Achilles Therapeutics

Focus: Achilles Therapeutics is a UK-based biotech company developing personalized cancer immunotherapies targeting neoantigens through T cell engineering. The company operates as a pre-revenue stage entity focused on a single therapeutic area: oncology.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Achilles Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Achilles Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

levonorgestrel intrauterine device

Contraception

N/A

IUD placement

Genital Tract Mucosal Immunity

N/A

Clinical Trials (1)

Help build intelligence for Achilles Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Working on differentiated neoantigen-targeted T cell therapy platform, a clinically validated approach with Phase 2 data in lung cancer (ATL001)
Early-stage biotech environment offers significant scientific autonomy and potential equity upside for those joining during development phase
Focused oncology player in high-growth immunotherapy space with specialized technical expertise requirements

Watch Out For

No active job openings reported; company appears to be at a plateau or contraction phase with zero current hiring
Pipeline shows concerning data quality (contraceptive and HIV programs listed alongside oncology focus suggest database errors or portfolio misalignment); unclear strategic direction
Pre-revenue stage with no disclosed funding, cash position, or financial trajectory creates compensation and stability uncertainty

Generated by Claude from Achilles Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.